"This ANDA acquisition is a milestone event for Bayshore" said Mark Moshier, President of Bayshore
Short Hills, NJ (PRWEB) May 30, 2012
Bayshore Pharmaceuticals announces that it has acquired a pending Abbreviated New Drug Application (“ANDA”) via an Asset Purchase Agreement with a large US-based generic pharmaceutical company. Based on industry sales data, the product, which is expected to gain full FDA approval within the next quarter, has reported U.S. sales of approximately $12 million over the previous 12 month period.
“This ANDA acquisition is a milestone event for Bayshore, in that, once approved, this product is expected to become Bayshore’s first, fully owned, commercial product,” said Mark Moshier, President of Bayshore. “We are very excited with the many other projects at various stages of development with our external strategic partners and this acquisition will become the commercial platform for these other ANDA products. In addition to these internally funded projects, our Sales & Marketing activities are also gearing up in anticipation of the commercial sales and distribution of our many manufacturing partner’s FDA-approved generic products.”
About Bayshore Pharmaceuticals:
Bayshore Pharmaceuticals is a privately-held full service Pharmaceutical Sales & Marketing company founded in 2011 and based in Short Hills, NJ. Bayshore focuses on the generic prescription drug marketplace, developing and commercially manufacturing off-patent solid oral dose, semi-solid, ophthalmic and injectable products utilizing its global network of FDA-approved partners. The Bayshore label is fully-licensed, and via our strategic relationship with Granard Pharmaceutical Sales & Marketing, will provide access to all major trade distributors, wholesalers, retail pharmacy and mass merchandise chains and mail order outlets. All of Bayshore’s products and our respective partners fully recognize and comply with the highest quality standard, as per US-FDA requirements, and we emphasize the importance of project management to deliver on our commitments in a timely and reliable manner.
For Further Information, please contact:
Mark Moshier, President